IvabradineEarly Ivabradine and Beta-Blocker Treatment Impact on Decompensated Heart Failure

This study focuses on the effects of a medication called Ivabradine on Egyptian patients with a heart condition known as heart failure with reduced ejection fraction (rEF HF). The main goal is to determine if early use of Ivabradine alongside B-blockers can improve clinical outcomes and biomarkers associated with this condition. The study is important as it aims to find better treatment approaches for heart failure, potentially improving patients' quality of life and reducing the risk of severe symptoms and complications. During the study, participants are randomly assigned to one of two groups. One group receives early treatment with Ivabradine and B-blockers, while the other follows the American Heart Association's standard treatment guidelines for rEF HF. The study measures various aspects such as heart rate, blood pressure, symptoms of breathlessness, and orthopnea. It also assesses the NYHA class, serum levels of Pro-NT-BNP and ST2, left ventricular ejection fraction through echocardiography, and scores from the Minnesota Living with Heart Failure Questionnaire. These assessments are conducted at the beginning, after 2 weeks, and again after 3 months. The primary outcome of interest is the serum Pro-BNP level, which is an indicator of heart failure severity and can suggest worse clinical outcomes and increased mortality risk in heart failure patients.